Search results
Showing 46 to 60 of 70 results for lenalidomide
Awaiting development Reference number: GID-TA11753 Expected publication date: TBC
Lenalidomide with R-CHOP for untreated activated diffuse large B-cell lymphoma [ID1611]
Discontinued Reference number: GID-TA10480
In development Reference number: GID-TA11749 Expected publication date: 10 June 2027
Discontinued Reference number: GID-TA10171
Awaiting development Reference number: GID-TA11815 Expected publication date: TBC
Awaiting development Reference number: GID-TA11830 Expected publication date: TBC
Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma (TA894)
Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for relapsed or refractory follicular lymphoma in adults.
transplantation. These studies were performed before thalidomide, bortezomib and lenalidomide were used as myeloma treatments.These...
Evidence-based recommendations on pembrolizumab (Keytruda) plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer in adults.
Discontinued Reference number: GID-TA10926
Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment (TA1001)
Evidence-based recommendations on zanubrutinib (Brukinsa) for marginal zone lymphoma after anti-CD20-based treatment in adults.
Evidence-based recommendations on elranatamab (Elrexfio) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.
Past technology appraisal appeals and decisions
Evidence-based recommendations on selinexor (Nexpovio) with dexamethasone for treating relapsed and refractory multiple myeloma after 4 or more treatments in adults.